Abstract Details

Title Injectable disease-modifying therapies cycling versus switching to fingolimod: a retrospective U.S. claims study of risk of MS related relapses

Topic Multiple Sclerosis

Presentation(s) P1 - (-)

Poster/Presentation
Number 375

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Xiangyi Meng, PhD (Novartis)	Dr. Meng has nothing to disclose.
	No disclosure on file
	No disclosure on file
Christen Kutz (Colorado Springs Neurological Associates)	No disclosure on file
Devon Conway, MD	Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Pharmaceuticals. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.